CD274 and non-small cell lung carcinoma: In the randomized phase III CheckMate-227 trial part 1 for untreated advanced NSCLC, patients with PD-L1 ≥ 1% (part 1a, N = 1189) showed a significant OS benefit in the nivolumab plus ipilimumab group versus the chemotherapy group (hazard ratio: 0.79, 95% CI 0.67–0.93) [31].